Literature DB >> 22855139

Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells.

Baoshan Cao1, Jun Jia, Liwen Ma, Lijun Di, Guohong Song, Yanhua Yuan, Bo Ma, Yulin Zhu, Jing Yu, Xiaoli Wang, Xinna Zhou, H Kim Lyerly, Jun Ren.   

Abstract

PURPOSE: To ascertain the biologic significance of lung cancer Side population (SP) cells, which represent putative cancer stem cells (CSC) in the absence of consensus biomarkers for tumor-specific CSC.
MATERIALS AND METHODS: We sorted and analyzed the angiogenic features of SP cells, isolated from tumor cell lines based on the exclusion of the DNA dye Hoechst 33342, from the NSCLC cell lines A549 and H460.
RESULTS: Compared with non-SP cells, mRNA of vascular endothelial growth factor (VEGF)-A, VEGF-B, angiopoietin (ang)-1, ang-2, fibroblast growth factor-2 (FGF-2), cyclooxygenase-2 (Cox-2) and interleukin-8 (IL-8) were over-expressed in SP cells accompanied by over-expression of ABCG2 and MDR1 mRNA. The supernatant of cultured SP cells could significantly induce migration of human umbilical vein endothelial cells, while recombinant human endostatin (Endostar 25(®)) could inhibit the migration.
CONCLUSIONS: This study revealed that the NSCLC SP cells might represent CSCs and possess pro-angiogenic properties, and antiangiogenesis represent a potential therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855139     DOI: 10.1007/s12094-012-0844-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  47 in total

Review 1.  Applying the principles of stem-cell biology to cancer.

Authors:  Ricardo Pardal; Michael F Clarke; Sean J Morrison
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

2.  Detection and enrichment of hematopoietic stem cells by side population phenotype.

Authors:  Shannon S Eaker; Teresa S Hawley; Ali Ramezani; Robert G Hawley
Journal:  Methods Mol Biol       Date:  2004

3.  [Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer].

Authors:  Lin Yang; Jin-wan Wang; Yan Sun; Yun-zhong Zhu; Xia-qing Liu; Wei-lian Li; Li-jun Di; Pei-wen Li; You-liang Wang; Shu-ping Song; Chen Yao; Li-fen You
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2006-02

4.  A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.

Authors:  G G Wulf; R Y Wang; I Kuehnle; D Weidner; F Marini; M K Brenner; M Andreeff; M A Goodell
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

Review 5.  New antiangiogenetic agents and non-small cell lung cancer.

Authors:  C Gridelli; A Rossi; P Maione
Journal:  Crit Rev Oncol Hematol       Date:  2006-07-13       Impact factor: 6.312

6.  Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis.

Authors:  Chih-Hsin Tang; Tzu-Wei Tan; Wen-Mei Fu; Rong-Sen Yang
Journal:  Carcinogenesis       Date:  2007-10-04       Impact factor: 4.944

7.  CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway.

Authors:  Zhongxing Liang; Joann Brooks; Margaret Willard; Ke Liang; Younghyoun Yoon; Seunghee Kang; Hyunsuk Shim
Journal:  Biochem Biophys Res Commun       Date:  2007-06-04       Impact factor: 3.575

8.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells.

Authors:  Maria M Ho; Alvin V Ng; Stephen Lam; Jaclyn Y Hung
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

9.  Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells.

Authors:  Yun Ling; Yong Yang; Na Lu; Qi-dong You; Sen Wang; Ying Gao; Yan Chen; Qing-Long Guo
Journal:  Biochem Biophys Res Commun       Date:  2007-07-10       Impact factor: 3.575

10.  Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas.

Authors:  G Fontanini; L Boldrini; S Chinè; F Pisaturo; F Basolo; A Calcinai; M Lucchi; A Mussi; C A Angeletti; G Bevilacqua
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

View more
  5 in total

1.  Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor.

Authors:  Chun Huang; Xuan Wang; Jing Wang; Li Lin; Zhujun Liu; Wenjing Xu; Liuchun Wang; Jianyu Xiao; Kai Li
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500

Review 2.  Regulation of miRNAs affects radiobiological response of lung cancer stem cells.

Authors:  Yan-mei Xu; Xing-yun Liao; Xie-wan Chen; De-zhi Li; Jian-guo Sun; Rong-xia Liao
Journal:  Biomed Res Int       Date:  2015-03-01       Impact factor: 3.411

3.  Wnt5A regulates ABCB1 expression in multidrug-resistant cancer cells through activation of the non-canonical PKA/β-catenin pathway.

Authors:  Tsai-Hsien Hung; Sheng-Chi Hsu; Ching-Yi Cheng; Kong-Bung Choo; Ching-Ping Tseng; Tse-Ching Chen; Ying-Wei Lan; Tsung-Teng Huang; Hsin-Chih Lai; Chuan-Mu Chen; Kowit-Yu Chong
Journal:  Oncotarget       Date:  2014-12-15

4.  Inactivation of p38 MAPK contributes to stem cell-like properties of non-small cell lung cancer.

Authors:  Yan Fang; Juan Wang; Guanwen Wang; Chen Zhou; Peng Wang; Shuangtao Zhao; Shaorong Zhao; Shan Huang; Weijun Su; Pengling Jiang; Antao Chang; Rong Xiang; Peiqing Sun
Journal:  Oncotarget       Date:  2017-04-18

5.  Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study.

Authors:  Jing-Jing Ge; Cheng Li; Shao-Pei Qi; Feng-Jun Xue; Zhi-Meng Gao; Chun-Jiang Yu; Jun-Ping Zhang
Journal:  BMC Cancer       Date:  2020-01-08       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.